Hypertrophic pachymeningitis (HP). overview of the underlying etiology, presentation & management
International Journal of Pharmaceutical Research, ISSN: 0975-2366, Vol: 11, Issue: 1, Page: 602-610
2019
- 2Citations
- 21Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Hypertrophic pachymeningitis (HP) is a rare chronic inflammatory dural pathology. It is classified into idiopathic by exclusion, or associated with underlying pathology like tuberculous meningitis, rheumatoid arthritis, syphilis, Wegener’s granulomatosis, IgG4 related disease and neoplasm. Objective: we try to review the etiology, clinical presentation & management & to review the literature on HP. this was retrospective study of 12 patients (7 men, 5 women), with age range between 20 to 75 years), they were diagnosed as HP (8 cranial & 4 spinal) by imaging studies & histopathology. The clinical features, serological, biochemical & radiological studies, treatment & outcome were followed over one year. The underlying etiology were so that 5 cases were idiopathic (IHP), 3 cases were associated with tuberculous meningitis, 2 cases were diagnosed in patients with rheumatoid arthritis & 2 cases were confirmed to be IgG4 related disease. The main clinical features at presentation were headache, cranial nerves neuropathy in cranial HP & limb sensory/motor dysfunction in spinal HP. On MRI, the enhancement & thickening of the dura mater correlated with the clinical presentation. Histopathological study from 8 patients demonstrated infiltrates of small mature lymphocytes, plasma cells, macrophages and epithelioid histiocytes. Corticosteroid therapy improved or stabilized the condition in 9 of 12 cases. Four cases need surgical intervention & have improvement. Three cases had progressive worsening & deterioration despite steroid therapy, two of them refused surgery & referred for chemotherapy but we missed them from our study without a feedback. Follow-up MRI performed in all patients. the diagnosis of HP is based on serological, MRI & histopathological studies. Idiopathic cases were diagnosed by exclusion. Steroid therapy control the disease progression. In symptomatic cases with mass effect & neurodeficit, surgery is indicated.
Bibliographic Details
SynthesisHub Advance Scientific Research
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know